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Multiple biological pathways often work together to determine a given disease phenotype. Understand-
ing what these pathways are and how they cooperate in disease-relevant biological processes is critical to
our understanding of diseases. Using microarray gene expression data, researchers have developed sev-
eral methods to rank pathways by their disease relevance. However, the exact set of pathways involved
and how they are involved under given disease conditions remain unclear. In this paper, we propose a
novel method to ﬁrst select a robust set of pathways that together best classify a given disease, and then
investigate how genes in these pathways interact to determine the phenotype. By applying our method to
several disease related microarray gene expression datasets, we detected many disease-relevant interac-
tion patterns supported by evidence from the literature. Our algorithm also achieves higher accuracy in
terms of identiﬁcation of a robust set of disease-relevant pathways when compared with alternative
strategies.
Published by Elsevier Inc.1. Introduction
It has been widely accepted that biological pathways often
function cooperatively to produce appropriate physiological re-
sponses to both internal and external stimuli [1,2]. Interaction or
crosstalk between pathways can be used to explain how multiple
pathways might act together to account for the observed pheno-
types [3]. Understanding pathway interactions will enhance our
understanding of the control and regulation of pathways as well
as consequently will provide us with deeper insight into the under-
lying cellular mechanisms. To explore pathway interactions, sev-
eral computational methods have been developed by
systematically combining both pathway data and protein–protein
interaction (PPI) data [1,4]. The assumption is that two pathways
are likely to interact with each other if there are signiﬁcantly more
protein interactions detected between these two pathways than
expected by chance. All of these computational methods interpret
a pathway as a cluster in PPI network and deﬁne pathway interac-
tion as PPI between pathways. However, strictly speaking, a cluster
in a PPI network is not a pathway because a pathway represents a
sequential molecular events, while PPI does not reﬂect the sequen-
tial relationship of pathway components, i.e., protein A interact
with protein B does not tell whether protein A’s activity causes
B’s activity or B’s activity causes A’s activity. Additionally, anInc.
412, University of Central
, USA. Fax: +1 407 823 5835.important prerequisite for the existence of a pathway interaction
is the simultaneous activation/involvement of at least two path-
ways in the same cell [5]. Therefore, it makes more sense to study
interactions among pathways that are relevant to a given disease
or phenotype.
Genes or pathways capable of characterizing diseases have been
computationally inferred from microarray gene expression data
[6–8]. Compared with those individually identiﬁed suspected dis-
ease genes, computationally inferred disease-relevant pathways
usually have better biological interpretability [9,10]. However,
multiple pathways could be inferred as disease-relevant, little
study has been carried on investigating which pathways together
are able to best delineate the disease mechanisms. The relationship
between different disease-relevant pathways remains unclear.
In this paper, we propose a novel approach to identify possible
interactions between different pathways which together deter-
mine a given disease phenotype. With the accumulation of anno-
tated pathways in public databases, our method will facilitate
biological hypothesis generation for disease classiﬁcation and
diagnosis.
The proposed approach is divided into two main steps. The ﬁrst
step applies a novel algorithm Recursive Random Forests (RRF) to
identify a robust set of disease-relevant pathways that are able
to best characterize the disease phenotype. The RRF algorithm is
based on the random forest (RF) algorithm [11], which is a tree-
based classiﬁcation and regression method (further detailed in Sec-
tion 2.2). The rationale is that a robust set of disease-relevant path-
ways together should be the best classiﬁer for the disease
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technique to investigate the interaction patterns among genes
from different pathways. The key idea of this step is supported
by the capability of the RF algorithm to grow many classiﬁcation
trees/forests from different subsets of predictors and observations,
and then this information is used to generate a prediction by
aggregating votes from all the trees. Each of these classiﬁcation
trees represents a classiﬁcation process. From many classiﬁcation
processes, we can mine possible gene/pathway interaction pat-
terns. We reason that genes from different pathways, if frequently
coexisting/co-occurring in multiple random classiﬁcation pro-
cesses, should implicate associations between their corresponding
pathways. We applied our approach to several disease microarray
datasets and identiﬁed many frequently co-occurring genes from
different pathways, implicating interaction patterns between dif-
ferent disease-relevant pathways supported by the literature.2. Methods
2.1. Data collection
We collected a total of 263 pathways from the BioCarta data-
base [12], and 187 pathways from the KEGG database [13]. Most
of the KEGG pathways are related to metabolism, degradation
and biosynthesis, whereas most of the BioCarta pathways are sig-
naling transduction pathways.
We also downloaded four microarray datasets from NCBI GEO
database and published literature. The breast cancer dataset [14]
consists of gene expression samples from 49 patients with large
operable or locally advanced breast cancers. Three sample classes
including basal, luminal and molecular apocrine have been ob-
tained previously via Principal Components Analysis and hierarchi-
cal clustering. The p53 dataset contains gene expression patterns
from 50 of the NCI-60 collection of cancer cell lines. Among the
50 cancer cell lines, 33 have been classiﬁed as carrying mutations
in the gene and 33 as no mutations in the gene [15]. The essential
thrombocythemia (ET) dataset consists of samples from 16 pa-
tients. Among these 16 samples, 9 samples have the JAK2V617F
mutation and 7 samples do not have the JAK2V617F mutation
[16]. The last dataset is the Michigan group lung dataset consisting
of samples from 86 patients, 24 of these 86 samples have poor out-
comes, and 62 of these 86 samples have good outcomes [17]. All
the expression data has been preprocessed as described in the ori-
ginal publication.2.2. RF classiﬁcation algorithm
Aswementioned before, the RF algorithm is a powerful machine
learning method that constructs a large number of classiﬁcation
trees and then aggregates the results from these trees. The RF algo-
rithm was originally developed by Leo Breiman and Adele Cutler.
Currently, there are many open source implementations, such as
the R implementation by Andy Liaw and Matthew Wiener (http://
cran.r-project.org/web/packages/randomForest/index.html). Here
is the procedure by which RF constructs one random tree. First, RF
will draw a group of bootstrap samples from the original data. Then,
basedon this groupof samples, RFwill growanun-pruned tree in the
following way: at each node, randomly sample a pre-deﬁned num-
ber of the predictors and choose the best split from among those
variables. With one new tree constructed, RF will calculate the clas-
siﬁcation error rate of the random forest constructed so far, by using
the out of bag (OOB) samples (all the samples excluding the corre-
sponding bootstrap samples). Therefore, for RF, it is in general no
need toperformcross-validationor a separate test set to get anunbi-
ased estimate of the test set error. In this paper, we construct RF byusing the sample types (such asdifferent cancer samples andnormal
samples) as response variables and using all the genes in all the
known pathways as predictor variables. The RF algorithm will out-
put all the classiﬁcation trees and their classiﬁcation error rates.
Each predictor variable, such as a gene, will also be assigned an
importance value using the measurement of ‘‘Mean Decrease in
Accuracy”.
To understand how several pathways work together, we can
simply rank pathways based on disease classiﬁcation error from
the above RF algorithm and then use the identiﬁed top relevant
pathways together as the classiﬁer. However, the obtained top rel-
evant pathways together may not be the best classiﬁer in terms of
classiﬁcation error rate because of the complicated interactions
among pathways. We thus develop the following RRF algorithm
to identify a robust set of disease-relevant pathways that together
have the best classiﬁcation performance.
2.3. RRF algorithm
The RRF algorithm is developed by recursively calling the RF
algorithm. Recursively applying a classiﬁcation method to produce
a robust feature set has been seen in many feature selection algo-
rithms. For example, recursively applying an SVM classiﬁer has
achieved good performance in selecting important genes from
microarray gene expression data [18,19]. Note that in genomics
and proteomics studies, the performance of the RF algorithm has
been shown to be comparable to or better than other machine
learning methods such as SVMs [20–22]. In the following, we detail
the parameter setup and implementation of the RRF algorithm to
identify a robust set of disease-relevant pathways.
We ﬁrst rank all the input pathways based on the error rate
corresponding to classifying different sample types by each indi-
vidual pathway. Then, starting from the top 10% of pathways with
the smallest error rates, we try to pinpoint pathways that may
work together and thus have the smallest error rates in distin-
guishing the sample types. Assume the number of the top 10%
pathways is n. We determine which n  1 pathways have the
smallest error rates by removing each of the n pathways once
and only once and implementing the RF algorithm on the remain-
ing pathways. With the best n  1 pathways, we keep removing
one pathway similarly to obtain the best n  2 pathways, n  3
pathways, and so on, until there is only one pathway left. The
group of pathways with the smallest error rate in this process
is then chosen as an ensemble to explain the observed sample
types.
In this paper, we applied the R implementation of RF (version
v4.5-30) from the R program (http://www.r-project.org). The num-
ber of classiﬁcation trees to be generated can be speciﬁed by the RF
algorithm. Considering the number of predictor genes (3911), we
set the number of classiﬁcation trees as 10,000 based on the rec-
ommendation of the RF function in R package for this study.
2.4. Frequent itemset mining (FIM) algorithm
A frequent itemset is a set of items that occur in more than a
user-speciﬁed percent of item transactions in a given database.
The user-speciﬁed percentage is called minimum support. A FIM
algorithm is to ﬁnd all frequent itemsets in a large transaction
database [23]. Let’s brieﬂy review FIM and related concepts. Let
I = {i1, i2,. . ., in} be a set of items and database D be a set of m trans-
actions, where each transaction T is a set of items such that T # D.
Let X be a set of items. A transaction T is said to contain X if and
only if X # T. X is frequent if at least s transactions in the database
contain X. By regarding each gene in a classiﬁcation tree as one
item and each classiﬁcation tree as one transaction in a database,
the problem of identifying frequently co-occurring genes in a large
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In this paper, we employed the FP-tree-based FIM algorithm [24].
The input parameter of FIM is the minimum support threshold a.
A gene pair is called frequently co-occurring if its absolute support
is larger or equal to this threshold. The FIM algorithm will be able
to output all possible gene pairs that co-occurring in at least a of
classiﬁcation trees generated by RF. To determine a, we start from
a equal to 1% to output the frequent patterns for all datasets, and
then iteratively increase a until there is little difference between
frequent pattern number for current a and previous a. The mini-
mum support threshold a is deﬁned as 5% in our study on 10,000
classiﬁcation trees generated by the RF algorithm.
2.5. Identify gene pairs frequently co-occurring in many classiﬁcation
trees
To investigate the relationship between multiple disease-rele-
vant pathways, we designed the approach illustrated in Fig. 1 to
identify gene pairs frequently co-occurring in many classiﬁcation
trees. We are interested only in gene pairs containing genes from
different pathways. Our approach is detailed below.
We ﬁrst use the RRF algorithm to select the robust set of dis-
ease-relevant pathways that can serve as the best phenotype clas-
siﬁer. With all the genes included in the identiﬁed important
pathways as predictor variables, we then apply the RF algorithm
to perform the classiﬁcation. The RF algorithmwith pathway genes
as predictor variables results in a speciﬁed large number of differ-
ent classiﬁcation trees corresponding to different classiﬁcation
processes. In each of these classiﬁcation trees, an internal node
stands for the expression value of a gene and a leaf node represents
a class prediction. Thus, all the genes involved in one classiﬁcation
tree form a gene group and participate in the same classiﬁcation
process. Even though the classiﬁcation trees generated by the RF
algorithm mostly likely do not correspond to a complete biologicalFig. 1. Algorithm pipeline for identifying frequentlprocess or pathway, intuitively, if two genes often participate in
the same classiﬁcation processes, then the two genes are more
likely to be cooperatively participating in the same biological pro-
cess. Based on this assumption, we then apply the FIM algorithm to
identify the gene pairs frequently co-occurring in RF classiﬁcation
processes. We then evaluate the statistical signiﬁcance for each of
the frequently co-occurring gene pairs and combine all the signif-
icant gene pairs to construct a frequently co-occurring gene net-
work in which two genes in a signiﬁcant gene pair are connected
by an edge. A network obtained in this way is able to provide us
with a global view of how different pathways can work together
to determine a disease phenotype.
To evaluate the signiﬁcance of a frequent co-occurring gene pair
discovered by the FIM algorithm, we implement the following pro-
cedure. We ﬁrst calculate the distribution of the frequency that a
gene occurs in the random forest. With such a distribution, we sim-
ulate a large number of trees by assuming these genes occur inde-
pendently, and count the number of trees where two genes co-
occur. We then use the frequency that two genes co-occur in a tree
as an estimate of the probability that two random genes will co-oc-
cur in a tree. With such probability p, we then use the Binomial
distribution to calculate the p-value of observing two genes occur-
ring in at least m trees. We claim the frequent gene pairs with
p-value less than 0.01 after Bonferroni correction as signiﬁcant
gene pairs.3. Results and discussion
To test our method, we have applied our algorithm to four dis-
ease related microarray datasets, including those of breast cancer,
lung carcinoma, essential thrombocythemia (ET) and the NCI-60
collection of cancer cell lines. The collection of the four datasets
is further described in Section 2.y co-occurring gene sets from random forests.
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As we discussed in Section 2, we ﬁrst applied RRF to identify
pathways which can best classify disease phenotype and are thus
most relevant to a given disease phenotype. The identiﬁed path-
ways are listed in Table 1. The classiﬁcation error is indicated by
the OOB error rate. Recall that OOB error rate is the classiﬁcation
error rate of the constructed RF on the ‘‘out of bag” samples. The
phenotype-relevance of many of the discovered pathways is sup-
ported by literature detailed below.
For the breast cancer data, which contains both estrogen recep-
tor positive and estrogen receptor negative samples, we have iden-
tiﬁed nine pathways by the RRF algorithm including the GATA3
pathway, down-regulation of MTA-3 in ER-negative breast tumors,
and the g-Secretase mediated ErbB4 signaling pathway. Most of
these pathways are well-known breast cancer relevant pathways.
For example, quite a few recent studies have shown that GATA3
could be a good prognostic biomarker in breast tumors [25–27].
Speciﬁcally, GATA3 expression levels have been shown to be very
different between the luminal-A subtype of breast cancer and the
basal-like subtype of breast cancer. There is also tentative data
showing that different polymorphisms of the GATA3 gene may
associate with differential susceptibilities to breast cancer [28].
Both the pathway resulting in the down-regulation of MTA-3 in
ER-negative breast tumors, and the g-Secretase mediated ErbB4
signaling pathway are also well-known to be associated with
breast cancer [29,30]. A very recent study has linked GATA3 to
estrogen receptors by meta-analysis of human cancer microarrays
[31]. The overall OOB error rate for using all nine pathways as a
classiﬁer is 0.091. This indicates that 9.1% of the samples could
be misclassiﬁed.
As we have described before, ET data contains both samples
with the JAK2 V617F mutation and samples without the JAK2
V617F mutation. For patients with JAK2 V617F mutation, the ki-
nase activity of JAK2V617F activates the JAK/STAT pathway,
whereas, those without JAK2 V617F will not have an activated
JAK/STAT pathway [32]. By applying our approach on ET data, we
identiﬁed a group of ﬁve pathways including the methane metab-Table 1
Important disease pathways selected by the RRF algorithm. The RRF alg
the pathways with the smallest OOB error rates are used as the input for
that the remaining pathways have the best OOB error rate. The progra
Data set Selected pathways by Recursiv
Breast cancer Adherens junction pathway
GATA3 pathway
Down regulated of MTA-3 in E
Alanine and aspartate metabol
Pyruvate metabolism pathway
g-Secretase mediated ErbB4 sig
IL 6 signaling pathway
Gap junction pathway
Deregulation of CDK5 in Alzhe
ET Methane metabolism
Prion disease
HIV induced T cell apoptosis
Fatty acid biosynthesis
Dentatorubropallidoluysian atr
p53 p53 Signaling pathway
Inﬂuence of Ras and Rho prote
Cell cycle: G1/S check point
Cell cycle pathway
Michigan lung IL 4 signaling pathway
TNFR1 signaling pathway
Activation of PKC through G pr
Extrinsic prothrombin activatio
Vitamin C in the brain
TSP1 induced apoptosis in micolism pathway, the prion disease pathway, HIV induced T cell
apoptosis, Fatty acid biosynthesis, and the Dentatorubropallidoluy-
sian atrophy pathway. Most of these pathways are closely related
to the JAK2 mutation. For example, the pathway resulting in the
IL-3-induced tyrosine phosphorylation of JAK2, STAT5A, and
STAT5B signaling proteins, has been shown to be associated with
the pathogenesis of CNS (central nervous system) diseases such
as prion disease [33]. The JAK2 mutation also activity leads to
growth inhibition and apoptosis in cells, thus potentially affect T
cell apoptosis pathway [34].
The p53 dataset contains gene expression patterns from 50 of
the NCI-60 collection of cancer cell lines. Among the 50 cancer cell
lines, 33 have been classiﬁed as carrying mutations and 17 as no
mutations [15]. Using our method, we identiﬁed the p53 signaling
pathway, a pathway involving the inﬂuence of Ras and Rho pro-
teins on the G1 to S transition, and cell cycle pathways. Most of
these pathways are consistent with those discovered in the litera-
ture. For example, the p53 signaling pathway has been reported in-
volved in 50 of the NCI-60 cell lines, and a subset of genes encoding
proteins in the p53 signaling pathway can causes cell cycle arrest
in response to DNA damage [35].
Finally, the Michigan lung carcinoma dataset contains 86 pa-
tient samples, in which 24 have poor outcomes and 62 have good
outcomes. Our method discovered six pathways including the
interleukin 4 signaling pathway, the tumor necrosis factor receptor
signaling pathway and the PKC activation pathway. Both the inter-
leukin 4 and tumor necrosis factor receptor have been shown to
have their associations with various cancer types. It has been re-
ported certain lung cancer cell lines show enhanced phosphoryla-
tion and altered expression of speciﬁc PKC isoforms compared with
normal lung epithelial cells [36–38]. The pathway of TSP1 (throm-
bospondin 1) induced apoptosis in microvascular endothelial cell
has also been demonstrated to be relevant to lung cancer [39,40].
3.2. Gene pairs frequently co-occurring in classiﬁcation forests
To investigate how genes in multiple disease-relevant pathways
work together to determine disease phenotype, for each dataset,orithm recursively calls the RF algorithm. At the beginning, 10% of
the RRF algorithm. Then recursively one pathway is removed such
m terminates when there is only one pathway left.
e Random Forests OOB
0.091
R-negative breast tumors pathway
ism pathway
naling pathway
imers disease pathway
0.100
ophy
0.120
ins on G1 to S Transition
0.188
otein coupled receptor
n pathway
rovascular endothelial cell
Table 2
Frequently co-occurring genes in random forests generated for the breast cancer
dataset.
Frequently co-occurred genes
for the breast cancer data set
Frequency of co-occurrence
(out of 10,000)
p-Value
ESR1 GATA3 958 0
IL6ST GATA3 837 0
ABAT GATA3 762 0
MAPT GATA3 749 0
IL6ST ESR1 701 0
ABAT ESR1 660 0
MAPT ESR1 634 0
ERBB4 GATA3 622 0
SOS1 GATA3 620 0
SOS1 ESR1 609 0
MAPT IL6ST 574 9.10E-13
IGF1R GATA3 573 1.26E-12
ERBB4 ESR1 573 1.26E-12
TCF7L1 GATA3 545 5.00E-09
ERBB2 GATA3 534 8.70E-08
PRKX GATA3 523 1.20E-06
PDHA1 GATA3 521 1.89E-06
IGF1R MAPT 519 2.94E-06
TUBB6 GATA3 513 1.06E-05
Table 3
Frequently co-occurring genes in random forests generated for the p53 dataset.
Frequently co-occurred genes
for P53 data set
Frequency of co-occurrence
(out of 10,000)
p-Value
CDKN2D CDKN1A 699 0
CDKN1A BAX 680 0
MDM2 BAX 603 8.95E-11
MDM2 CDKN1A 590 3.17E-09
RAC1 CDKN1A 561 3.10E-06
CDKN2D BAX 550 2.84E-05
ATR BAX 514 0.008527
MDM2 CDKN2D 512 0.010913
RAC1 BAX 511 0.012312
RELA BAX 510 0.013864
Table 4
Frequently co-occurring genes in random forests generated for the ET dataset.
Frequently co-occurred
genes for ET dataset
Frequency of co-occurrence
(out of 10,000)
p-Value
FASN CAT 772 0
ACACB CAT 529 0
HSPA5 CAT 522 0
Table 5
Frequently co-occurring genes in random forests generated for the Michigan lung
carcinoma dataset.
Frequently co-occurred genes for
Michigan lung carcinoma data set
Frequency of co-occurrence
(out of 10,000)
p-Value
CD36 SLC2A1 998 0
RPS6KB1 SLC2A1 951 0
IL4R SLC2A1 861 0
FADD SLC2A1 830 0
JAK3 SLC2A1 808 0
ARHGDIB IL4R 801 0
RPS6KB1 IL4R 735 0
IL4R FADD 680 0
ARHGDIB SLC2A1 671 0
CD36 IL4R 670 0
CD36 FADD 664 0
JAK3 IL4R 632 0
SPTAN1 SLC2A1 620 0
ARHGDIB FADD 616 0
TNF SLC2A1 612 0
CD36 ARHGDIB 610 0
ARHGDIB RPS6KB1 602 0
CD36 RPS6KB1 592 0
JAK3 FADD 587 0
ADPRT SLC2A1 569 1.11E-16
CASP2 SLC2A1 553 4.12E-14
AKT1 SLC2A1 546 4.54E-13
COL4A4 SLC2A1 541 2.38E-12
RELA SLC2A1 538 6.29E-12
PRKCA SLC2A1 523 6.25E-10
JAK3 ARHGDIB 522 8.36E-10
JAK3 RPS6KB1 515 6.06E-09
ADPRT ARHGDIB 514 7.98E-09
ADPRT CD36 508 3.99E-08
ADPRT FADD 506 6.71E-08
PAK1 SLC2A1 504 1.12E-07
NFKB1 SLC2A1 502 1.85E-07
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genes contained in all the important pathways previously obtained
from RRF. We thus extracted many frequently co-occurring gene
pairs containing genes from different pathways. We evaluated
the statistical signiﬁcance of each identiﬁed gene pair by the pro-
cedure described in Section 2 and obtained many interesting fre-
quently co-occurring gene pairs detailed below.
For the breast cancer dataset, after we applied the FIM algo-
rithm on the 10,000 random classiﬁcation trees constructed from
the nine important pathways identiﬁed previously from the RRF
algorithm, we obtained the frequently co-occurring gene pairs
shown in Table 2. The most frequently co-occurring gene pair is
estrogen receptor 1 (ESR1) and GATA binding protein 3 (GATA3).
GATA3 and ESR1 have been shown to co-express in human breast
cancers due to a very interesting co-regulatory relationship be-
tween ESR1 and GATA3 formulated by both the binding of GATA3
to two cis-regulatory elements located within the ESR1 gene for
RNA polymerase II recruitment to ESR1 promoters, and the direct
transcription stimulation of the GATA3 gene by ESR1 [41]. Since
GATA3 and ESR1 correspond to two different pathways: the GATA3
signaling pathway and the down-regulation of MTA-3 in ER-nega-
tive breast tumors pathway, the robust relationship between
GATA3 and ESR1 indicates the likely possibility that the two path-
way work together through the two genes. Similar phenomena
have been observed for other frequent gene pairs such as IL6ST
and ESR1, IL6ST and GATA3, and MAPT and GATA3.
For p53 dataset, we identiﬁed a number of frequently co-occur-
ring gene pairs shown in Table 3 such as cyclin-dependent kinaseinhibitor 1A (CDKN1A) and BCL2-associated X protein (BAX), cy-
clin-dependent kinase inhibitor 2D (CDKN2D) and CDKN1A, and
MDM2 and BAX. BAX belongs to the p53 signaling pathway, and
thus its relevance to the p53 related phenotype is obvious. Both cy-
clin-dependent kinase inhibitors such as CDKN1A and CDKN2D are
members of cell cycle pathways. The frequently co-occurring rela-
tionship of these genes could indicate how the p53 signaling path-
way and the cell cycle pathway work together in tumor cells.
Only three signiﬁcantly co-occurring gene pairs were identiﬁed
from the ET dataset including the catalase (CAT) gene from the
methane metabolism pathway, heat shock 70 kDa protein 5
(HSPA5) from the prion disease pathway, and acetyl-Coenzyme A
carboxylase beta (ACACB) and fatty acid synthase (FASN) from
the fatty acid metabolism pathway (Table 4). We have discussed
the relevance of these pathways to the JAK2 mutation in the previ-
ous section. Here the association of catalase with fatty acid syn-
thase related genes indicates the interplay between methane
metabolism and fatty acid metabolism in the context of the JAK2
mutation.
More frequently co-occurring gene pairs listed in Table 5 are
identiﬁed from the Michigan lung dataset. These include CD36
molecule and the solute carrier family 2 member 1 gene (SLC2A1),
RPS6KB1 and SLC2A1, IL4R and SLC2A1, and so on. CD36, a member
Fig. 2. Frequently co-occurring gene network generated by summarizing frequently co-occurring genes identiﬁed from 10,000 random classiﬁcation trees using all genes in
all the important pathways as predictors. The important pathways are selected by the RRF algorithm from a breast cancer dataset (a), a p53 dataset (b), an ET dataset (c), and
the Michigan lung dataset (d). Only nodes corresponding to genes from the same pathway are labeled with the same color. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
Table 6
Thirteen top ranked important genes generated by the RF algorithm when applied to all the genes in all the nine important pathways selected by the RRF
algorithm for the breast cancer dataset.
Gene symbol Estrogen receptor
negative
Estrogen receptor
positive
Mean Decrease
in Accuracy
Present in the frequently
co-occurred gene network? (Y/N)
GATA3 0.056619 0.025994996 0.033922002 Y
ESR1 0.031663 0.008798428 0.014831312 Y
IL6ST 0.027416 0.010084513 0.014591713 Y
ABAT 0.023345 0.007054923 0.011409093 Y
MAPT 0.018764 0.006948131 0.010124841 Y
ERBB4 0.018776 0.006191934 0.00960001 Y
IGF1R 0.010619 0.004805728 0.006268051 Y
TUBB6 0.00549 0.00615204 0.005938743 Y
SOS1 0.006331 0.005706577 0.005855699 Y
TCF7L1 0.010265 0.003252455 0.005084944 Y
PRKX 0.00398 0.004579609 0.004435826 Y
YES1 0.005181 0.002359804 0.003114606 N
CEBPB 0.006294 0.001549499 0.002727519 N
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microvascular endothelial cells, is a thrombospondin 1 receptor
that is selectively expressed in the microvascular endothelium.
As we discussed before, TSP1 and SLC2A1 has been demonstrated
to be relevant to lung cancer [39,40,42].
We also combined all the frequently co-occurring genes as a
network, in which each frequently co-occurring gene pair is con-
nected by an edge. Genes belonging to different pathways are la-
beled with different colors. These frequently co-occurring gene
networks provide a global view of how different disease-relevantpathways work together to determine a certain phenotype. See
Fig. 2 for more examples.
In addition, we compared genes in the identiﬁed frequently co-
occurring gene pairs with top ranked important genes by the RF
algorithm when using all the genes in the selected pathways as
predictors. RF ranks important genes based on their individual con-
tribution to the classiﬁcations. As a result, we found that many top
ranked important genes overlapped with genes in the frequently
co-occurring gene pairs. For example, Table 6 lists the thirteen
top ranked important genes discovered by applying the RF algo-
Table 7
Important pathways selected by the RF algorithm.
Data set Top pathways obtained by random forests method OOB classiﬁcation error Overall classiﬁcation error
Breast cancer GATA3 pathway 0.1118881 0.112
Butanoate metabolism 0.1188811
Cell communication 0.1223776
Adherens junction 0.1223776
Lysine degradation 0.1328671
Nitrogen metabolism 0.1328671
Calcium signaling pathway 0.1328671
Alanine and aspartate metabolism 0.1363636
ET Methane metabolism 0.175 0.175
Carbon ﬁxation 0.275
Alkaloid biosynthesis I 0.275
Prion disease 0.275
HIV induced T cell apoptosis 0.3
p53 p53 Pathway 0.14 0.16
Regulation of BAD phosphorylation 0.14
Role of mitochondria in apoptotic signaling 0.14
Hypoxia and p53 in the cardiovascular system 0.16
Michigan lung Caspase cascade in apoptosis 0.2235294 0.247
IL4 signaling pathway 0.2235294
Fibrinolysis pathway 0.2352941
FAS signaling pathway 0.2352941
Blockade of neurotransmitter release by botulinum toxin 0.2470588
Cardiac protection against ROS 0.2470588
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The importance of a gene is measured by the statistic of Mean De-
crease in Accuracy deﬁned in the RF algorithm. Note that, Mean
Decrease in Accuracy is one type of measurements that measure
the importance of gene in classifying the samples in RF method.
One can refer to Pang et al. for detailed calculation [10]. A full
85% of these genes overlapped with genes in the frequently co-
occurring gene pairs we identiﬁed. This result indicates that the
majority of genes in our frequently co-occurring gene pairs are
important according to their phenotype classiﬁcation power.
3.3. Comparison with other methods
We ﬁrst compare the RRF algorithm with the RF algorithm,
which has been widely used in genomics and proteomic studies
and has demonstrated good performance when compared with
other machine learning methods [22]. As we discussed in the Algo-
rithms section, the RRF algorithm recursively applies the RF algo-
rithm to identify the best subset of pathways as phenotype
predictors. Alternatively, we can directly apply the RF algorithm
to form the best pathway subset by including only pathways with
the smallest OOB error rates. Here we want to compare the path-
ways identiﬁed from these two methods: RRF and RF. The compar-
ison is based on the overall classiﬁcation error, i.e., the OOB errorTable 8
Important pathways selected by the GSEA method.
Data set Top three pathways obtained by GSEA method
Breast cancer Repression of pain sensation by the transcriptional reg
CARM1 and regulation of the estrogen receptor
Circadian rhythm
ET Cell cycle: G2/M checkpoint
Cell cycle pathway
Role of EGF receptor trans-activation by GPCRs in card
p53 Nerve growth factor pathway
Ras signaling pathway
IGF-1 signaling pathway
Michigan lung VEGF, Hypoxia, and Angiogenesis
Insulin signaling pathway
p53 Signaling pathwayrate when using all the genes in the identiﬁed pathways as predic-
tors for phenotype classiﬁcation. The OOB error rates obtained by
the RRF algorithm and the RF algorithm are shown in Tables 1
and 7, respectively. From these listed OOB error rates, we can see
that the overall classiﬁcation errors for pathways identiﬁed by
the RRF algorithm are always smaller than the overall classiﬁcation
errors for pathways identiﬁed by the RF algorithm.
Next we compare the RRF algorithm to the GSEA algorithm, one
of the most popular methods used to computationally rank dis-
ease-relevant pathways [35]. Note that the problems of identifying
pathway-based disease classiﬁers and ranking disease-relevant
pathways are convertible in the sense that better disease classiﬁers
should have better disease relevance [10]. GSEA ranks all genes
based on expression correlation and given phenotypes, as well as
calculates a Kolmogorov–Smirnov-like (KS) score that reﬂects the
degree to which a given set of genes are represented at the ex-
tremes of the entire ranked list. When the input is all the genes
in a speciﬁc pathway, GSEA-like methods can output a p-value
reﬂecting the phenotype-relevance of the given pathway.
We ﬁrst compare the important pathways selected by RRF with
those disease-relevant pathways identiﬁed by the GSEA approach.
By setting p-value cut off as 0.001, GSEA output three pathways as
important for P53 dataset and Michigan lung dataset, and with the
same p-value cutoff, GSEA output none for the other two datasets.p-Value OOB classiﬁcation error
ulator DREAM 0.004 0.147
0.022
0.025
0.007 0.6
0.045
iac hypertrophy 0.036
0.002 0.38
0.002
0.008
0 0.294
0
0
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ways with smallest GSEA p-values for all the four datasets. We
then use these selected pathways to perform classiﬁcations using
RF. Table 8 shows the overall OOB error rate when using all of
the top three pathways as a classiﬁer. Comparing this error rate
with the OOB error rate we obtained using the RF algorithm and
the RRF algorithm, we ﬁnd that the pathways identiﬁed by RRF
show smaller classiﬁcation error rates in every dataset. This result
is not surprising because KS scoring in GSEA is not as good as OOB
classiﬁcation error measurement in RF and RRF algorithms in
terms of evaluating classiﬁcation errors.
4. Conclusions
In this paper, we have proposed a novel pathway analysis ap-
proach to investigate how genes in different disease-relevant path-
ways relate to each other during phenotype classiﬁcation. The
uniqueness of our approach lies in two aspects. One is that our
RRF algorithm is able to provide robust selection of pathways that
together can serve as the best classiﬁer in terms of having the
smallest ‘‘out-of-bag” classiﬁcation error. The other is that by using
the FIM algorithm to identify genes from different pathways fre-
quently co-occurring in many disease classiﬁcation processes, we
can efﬁciently discover potential interactions between different
pathways. There are also a couple of caveats. One is that current
collection of annotated pathways is far from complete, and there
might be some unknown disease-relevant pathways sharing
important genes with the identiﬁed important pathways. The other
is that although frequent co-occurrence of genes indicates a certain
degree of function association, the co-occurrence of these genes
does not signify direct physical interaction. This aspect distin-
guishes our method from those studies identifying possible path-
way interactions from protein interaction data. After being
applied to several experimental datasets, our approach has de-
tected many interesting patterns implicating pathway interactions
and has shown promise for facilitating future biological hypothesis
generation for disease classiﬁcation and diagnosis.
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